Pharmaceuticals, Biotechnology and Life Sciences
Celyad is about to kick the THINK trial in the USA, after the U.S. FDA authorized its initiation. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological malignancies.
Celyad has started on Thursday its Therapeutic Immunotherapy with NKR-2 (THINK) trial in Belgium with the first patient giving blood.
To remind, THINK trial is an open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers.